10/15/2025
Jennifer Wheeley, MS, FNP-C; Nikita Chintapally, MD; Kanchan Kulkarni, MD; Gabriel Yohe, MS; Priya Kundra, MD; Jennifer Rosen, MD; Muhammad M. Shaikh, MD; Meeta Sharma, MD; Jason Wexler, MD; Kenneth D. Burman, MD; Leila Shobab, MD; Irina Veytsman, MD
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted...
